Salem, NH, October 06, 2009 --(PR.com
)-- ALPCO Diagnostics, a leading developer and distributor of high quality immunoassay kits, is pleased to announce that they have signed with Athera Biotechnologies as their new distribution channel in the North America.
Sean Conley, COO of ALPCO, said “We are very excited about the opportunities presented by this agreement, which will enable us to offer a new CVD biomarker to customers in North America. CVDefine
® Anti Phosphorylcholine ELISA may add important and independent information in cardiovascular risk assessment and we believe there is a lot of interest from scientist in the field to use this to generate further clinical research data”.
High levels of IgM antibodies against phosphorylcholine (anti-PC) have been shown to be predictive of less atherosclerosis development in hypertensive patients after a five-year follow up. However, in 2008 data indicating that low anti-PC levels predict an increased risk of CVD were presented. One study included myocardial infarction (MI) patients and suggested that anti-PC measurements could be used to predict the likelihood of secondary CVD events up to six months after an initial event. This has since been followed up with another study involving over 1000 ACS patients. The product, CVDefine
®, was introduced last year and provides an easy-to-use ELISA kit (Research Use Only) for quantitative analysis of anti-PC in human blood.
“This distribution agreement is another important step for Athera as we expand in the North American market. This agreement broadens our presence and increases the exposure of our trademark. I am pleased with the opportunities this represents and I look forward to working with the efficient and experienced team from ALPCO”, says Carina Schmidt, CEO Athera Biotechnologies AB.
About ALPCO Diagnostics
ALPCO was founded in 1990 as an importer and distributor of high quality research immunoassay kits. Since that time, their primary goals have been to offer a diverse line of assays that appeal to their broad customer base while also providing exceptional customer service and product support.
About Athera Biotechnologies AB
Athera develops novel products for risk assessment and treatment of CVD. The company was founded in 2002 to exploit findings made by Professors Johan Frostegård and Ulf de Faire on the critical role of phospholipid antibodies (aPL) in the inflammatory process of early CVD. Athera has an innovative pipeline of risk markers and drug candidates and the possibility to provide a true combination of diagnosis and treatment.